The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
about
Persistent pharmacokinetic challenges to pediatric drug developmentUDP-glucuronosyltransferase 1a enzymes are present and active in the mouse blastocyst.Apiaceous vegetable consumption decreases PhIP-induced DNA adducts and increases methylated PhIP metabolites in the urine metabolome in rats.Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.Upregulation of Ugt1a genes in placentas and fetal livers in a murine model of assisted reproductionPlacental profiling of UGT1A enzyme expression and activity and interactions with preeclampsia at term.Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics.Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1)Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in childrenOne-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.Age-Dependent Hepatic UDP-Glucuronosyltransferase Gene Expression and Activity in Children.Obstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.Lobular Distribution and Variability in Hepatic ATP Binding Cassette Protein B1 (ABCB1, P-gp): Ontogenetic Differences and Potential for Toxicity.Extrahepatic metabolism at the body's internal-external interfaces.The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events.Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases.Theoretical pharmacokinetic drug alterations in pediatric celiac disease.Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffsDolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.Microsomal protein per gram of liver (MPPGL) in paediatric biliary atresia patients.Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.The effects of UDP-sugars, UDP and Mg2+on uridine diphosphate glucuronosyltransferase activity in human liver microsomes.A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.Allometry Is a Reasonable Choice in Pediatric Drug Development.
P2860
Q27023912-EBD108F0-877D-49C9-B6F7-1E7F4E2B521CQ34360024-BA1B7927-DDBB-4FFD-8B85-F01D8FE02F6EQ35107855-8128FDF3-37B8-4EBA-8D38-89A9E4CBAF58Q35607667-80C3CE13-AB7E-48C0-97D1-75E432FA042CQ35643443-71762428-761B-4517-B098-B4A9F0FB109CQ35952402-370A8766-3721-4C64-AAEB-1A735B25BC00Q36057407-DE48E252-FFD0-4504-A872-7251106EDAF9Q36501845-F242D5DA-FF1C-4F75-8F8D-C25ED32D78D9Q37062619-EF614132-AF47-47D8-8AE0-9982171FB95AQ37279407-7FF65F97-9075-4CF5-A47E-CB6C5AB3A149Q37335808-D799F393-A99F-46E9-A9DE-97D779517476Q37416072-BE3BC4A1-B3DE-4118-8742-F2ABFEA9ABCCQ37488244-79878CF4-8325-4D5D-8B32-6CBC99B48D0EQ37731228-49090CE0-6852-4CCA-B761-B72F5A71F55EQ38199198-38045637-6399-4981-AD4E-B2F158DE2E4FQ38234794-8E35D691-7955-414F-8937-385C8D39CE9DQ38386709-1DB396A8-CC49-4FFA-8A03-600F7F3AEC2CQ38544086-C022E4AB-C9B2-42E5-9C19-57161119AB85Q38854456-F27C2783-17F5-4E22-8DCC-A250D15FF225Q40181637-F1EE1006-AA19-4782-A9DC-32CB949AF223Q47156665-23ED7B71-6BD8-453B-ACEB-84A9FAB2B1E8Q47548999-D7EA4927-5537-4F0D-9F6B-8D7D66A48447Q49081907-09FBF71D-F945-49A8-B509-8D2BCB17105EQ50039487-B8D37F9E-171F-40E9-A2CA-98F563584AD3Q50226493-7C81F6F8-FA5A-4A96-9DC6-B1243935131DQ51013612-586329EB-9ED1-471F-A937-71A08EA87C4DQ54771792-AB1E4BEF-5FC1-4AE3-9E6F-969C8C15B085
P2860
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@ast
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@en
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@nl
type
label
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@ast
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@en
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@nl
prefLabel
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@ast
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@en
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@nl
P2860
P356
P1476
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver
@en
P2093
Abby C Collier
Shogo J Miyagi
P2860
P304
P356
10.1124/DMD.110.037192
P577
2011-01-25T00:00:00Z